Selected research
Industry Research
Neuroendocrine Carcinoma Industry Research Report 2026
Market perspective
The global Neuroendocrine Carcinoma market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Neuroendocrine Carcinoma market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Neuroendocrine Carcinoma market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Neuroendocrine Carcinoma market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Neuroendocrine Carcinoma include Teva, Novartis, Pfizer, Abbvie, Valeant, Mateon, Lexicon, Jubilant and Ipsen, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Neuroendocrine Carcinoma market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Neuroendocrine Carcinoma.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Neuroendocrine Carcinoma Market by Company
Teva
Novartis
Pfizer
Abbvie
Valeant
Mateon
Lexicon
Jubilant
Ipsen
F.Hoffmann-La Roche
Chiasma
Advanced Accelerator
Neuroendocrine Carcinoma Segment by Type
Somatostatin Analogs
Chemotherapy
Targeted Therapy
Neuroendocrine Carcinoma Segment by Application
Oncology Centres
Clinics
Hospital
Ambulatory Surgery Centres
Neuroendocrine Carcinoma Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuroendocrine Carcinoma market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Neuroendocrine Carcinoma and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuroendocrine Carcinoma.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Neuroendocrine Carcinoma companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Somatostatin Analogs
- Chemotherapy
- Targeted Therapy
Applications
- Oncology Centres
- Clinics
- Hospital
- Ambulatory Surgery Centres
Companies covered
- Teva
- Novartis
- Pfizer
- Abbvie
- Valeant
- Mateon
- Lexicon
- Jubilant
- Ipsen
- F.Hoffmann-La Roche
- Chiasma
- Advanced Accelerator
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Neuroendocrine Carcinoma by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Somatostatin Analogs
- 2.2.3 Chemotherapy
- 2.2.4 Targeted Therapy
- 2.3 Neuroendocrine Carcinoma by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Oncology Centres
- 2.3.3 Clinics
- 2.3.4 Hospital
- 2.3.5 Ambulatory Surgery Centres
- 2.4 Assumptions and Limitations
3 Neuroendocrine Carcinoma Breakdown Data by Type
- 3.1 Global Neuroendocrine Carcinoma Historic Market Size by Type (2021-2026)
- 3.2 Global Neuroendocrine Carcinoma Forecasted Market Size by Type (2027-2032)
4 Neuroendocrine Carcinoma Breakdown Data by Application
- 4.1 Global Neuroendocrine Carcinoma Historic Market Size by Application (2021-2026)
- 4.2 Global Neuroendocrine Carcinoma Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Neuroendocrine Carcinoma Market Perspective (2021-2032)
- 5.2 Global Neuroendocrine Carcinoma Growth Trends by Region
- 5.2.1 Global Neuroendocrine Carcinoma Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Neuroendocrine Carcinoma Historic Market Size by Region (2021-2026)
- 5.2.3 Neuroendocrine Carcinoma Forecasted Market Size by Region (2027-2032)
- 5.3 Neuroendocrine Carcinoma Market Dynamics
- 5.3.1 Neuroendocrine Carcinoma Industry Trends
- 5.3.2 Neuroendocrine Carcinoma Market Drivers
- 5.3.3 Neuroendocrine Carcinoma Market Challenges
- 5.3.4 Neuroendocrine Carcinoma Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Neuroendocrine Carcinoma Players by Revenue
- 6.1.1 Global Top Neuroendocrine Carcinoma Players by Revenue (2021-2026)
- 6.1.2 Global Neuroendocrine Carcinoma Revenue Market Share by Players (2021-2026)
- 6.2 Global Neuroendocrine Carcinoma Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Neuroendocrine Carcinoma Head Office and Area Served
- 6.4 Global Neuroendocrine Carcinoma Players, Product Type & Application
- 6.5 Global Neuroendocrine Carcinoma Manufacturers Established Date
- 6.6 Global Neuroendocrine Carcinoma Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Neuroendocrine Carcinoma Market Size (2021-2032)
- 7.2 North America Neuroendocrine Carcinoma Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Neuroendocrine Carcinoma Market Size by Country (2021-2026)
- 7.4 North America Neuroendocrine Carcinoma Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Neuroendocrine Carcinoma Market Size (2021-2032)
- 8.2 Europe Neuroendocrine Carcinoma Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Neuroendocrine Carcinoma Market Size by Country (2021-2026)
- 8.4 Europe Neuroendocrine Carcinoma Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Neuroendocrine Carcinoma Market Size (2021-2032)
- 9.2 Asia-Pacific Neuroendocrine Carcinoma Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Neuroendocrine Carcinoma Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Neuroendocrine Carcinoma Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Neuroendocrine Carcinoma Market Size (2021-2032)
- 10.2 South America Neuroendocrine Carcinoma Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Neuroendocrine Carcinoma Market Size by Country (2021-2026)
- 10.4 South America Neuroendocrine Carcinoma Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Neuroendocrine Carcinoma Market Size (2021-2032)
- 11.2 Middle East & Africa Neuroendocrine Carcinoma Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Neuroendocrine Carcinoma Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Neuroendocrine Carcinoma Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Teva
- 12.1.1 Teva Company Information
- 12.1.2 Teva Business Overview
- 12.1.3 Teva Revenue in Neuroendocrine Carcinoma Business (2021-2026)
- 12.1.4 Teva Neuroendocrine Carcinoma Product Portfolio
- 12.1.5 Teva Recent Developments
- 12.2 Novartis
- 12.2.1 Novartis Company Information
- 12.2.2 Novartis Business Overview
- 12.2.3 Novartis Revenue in Neuroendocrine Carcinoma Business (2021-2026)
- 12.2.4 Novartis Neuroendocrine Carcinoma Product Portfolio
- 12.2.5 Novartis Recent Developments
- 12.3 Pfizer
- 12.3.1 Pfizer Company Information
- 12.3.2 Pfizer Business Overview
- 12.3.3 Pfizer Revenue in Neuroendocrine Carcinoma Business (2021-2026)
- 12.3.4 Pfizer Neuroendocrine Carcinoma Product Portfolio
- 12.3.5 Pfizer Recent Developments
- 12.4 Abbvie
- 12.4.1 Abbvie Company Information
- 12.4.2 Abbvie Business Overview
- 12.4.3 Abbvie Revenue in Neuroendocrine Carcinoma Business (2021-2026)
- 12.4.4 Abbvie Neuroendocrine Carcinoma Product Portfolio
- 12.4.5 Abbvie Recent Developments
- 12.5 Valeant
- 12.5.1 Valeant Company Information
- 12.5.2 Valeant Business Overview
- 12.5.3 Valeant Revenue in Neuroendocrine Carcinoma Business (2021-2026)
- 12.5.4 Valeant Neuroendocrine Carcinoma Product Portfolio
- 12.5.5 Valeant Recent Developments
- 12.6 Mateon
- 12.6.1 Mateon Company Information
- 12.6.2 Mateon Business Overview
- 12.6.3 Mateon Revenue in Neuroendocrine Carcinoma Business (2021-2026)
- 12.6.4 Mateon Neuroendocrine Carcinoma Product Portfolio
- 12.6.5 Mateon Recent Developments
- 12.7 Lexicon
- 12.7.1 Lexicon Company Information
- 12.7.2 Lexicon Business Overview
- 12.7.3 Lexicon Revenue in Neuroendocrine Carcinoma Business (2021-2026)
- 12.7.4 Lexicon Neuroendocrine Carcinoma Product Portfolio
- 12.7.5 Lexicon Recent Developments
- 12.8 Jubilant
- 12.8.1 Jubilant Company Information
- 12.8.2 Jubilant Business Overview
- 12.8.3 Jubilant Revenue in Neuroendocrine Carcinoma Business (2021-2026)
- 12.8.4 Jubilant Neuroendocrine Carcinoma Product Portfolio
- 12.8.5 Jubilant Recent Developments
- 12.9 Ipsen
- 12.9.1 Ipsen Company Information
- 12.9.2 Ipsen Business Overview
- 12.9.3 Ipsen Revenue in Neuroendocrine Carcinoma Business (2021-2026)
- 12.9.4 Ipsen Neuroendocrine Carcinoma Product Portfolio
- 12.9.5 Ipsen Recent Developments
- 12.10 F.Hoffmann-La Roche
- 12.10.1 F.Hoffmann-La Roche Company Information
- 12.10.2 F.Hoffmann-La Roche Business Overview
- 12.10.3 F.Hoffmann-La Roche Revenue in Neuroendocrine Carcinoma Business (2021-2026)
- 12.10.4 F.Hoffmann-La Roche Neuroendocrine Carcinoma Product Portfolio
- 12.10.5 F.Hoffmann-La Roche Recent Developments
- 12.11 Chiasma
- 12.11.1 Chiasma Company Information
- 12.11.2 Chiasma Business Overview
- 12.11.3 Chiasma Revenue in Neuroendocrine Carcinoma Business (2021-2026)
- 12.11.4 Chiasma Neuroendocrine Carcinoma Product Portfolio
- 12.11.5 Chiasma Recent Developments
- 12.12 Advanced Accelerator
- 12.12.1 Advanced Accelerator Company Information
- 12.12.2 Advanced Accelerator Business Overview
- 12.12.3 Advanced Accelerator Revenue in Neuroendocrine Carcinoma Business (2021-2026)
- 12.12.4 Advanced Accelerator Neuroendocrine Carcinoma Product Portfolio
- 12.12.5 Advanced Accelerator Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst